Research programme: spinal muscular atrophy therapeutics - Lexicon Pharmaceuticals

Drug Profile

Research programme: spinal muscular atrophy therapeutics - Lexicon Pharmaceuticals

Alternative Names: SMN protein activators - Lexicon

Latest Information Update: 25 Nov 2014

Price : $50

At a glance

  • Originator Lexicon Genetics
  • Developer Lexicon Pharmaceuticals
  • Class
  • Mechanism of Action Survival of motor neuron 1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Spinal muscular atrophy

Most Recent Events

  • 27 Nov 2008 No development reported - Preclinical for Spinal muscular atrophy in USA (unspecified route)
  • 27 Apr 2007 Lexicon Genetics is now called Lexicon Pharmaceuticals
  • 13 Oct 2006 Lexicon has been awarded an additional grant from the US Army and Medical Research and Material Command for the development of drugs to prevent or treat Spinal muscular atrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top